Yixin Su

Zhongxiu Road
Lingcheng, 535400, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications

Adjuvant apatinib therapy following concurrent chemoradiotherapy in patients with high-risk nasopharyngeal carcinoma: A multicenter, prospective phase 2 study.

Adjuvant apatinib therapy following concurrent chemoradiotherapy in patients with high-risk nasopharyngeal carcinoma: A multicenter, prospective phase 2 study.

Journal: Translational oncology
Published: March 19, 2026

Efficacy and Safety of Vascular-Targeting Agents Plus Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients: A Multicenter Clinical Cohort Study.

Efficacy and Safety of Vascular-Targeting Agents Plus Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients: A Multicenter Clinical Cohort Study.

Journal: Cancer control : journal of the Moffitt Cancer Center
Published: September 29, 2025

An individualized immune prognostic signature in nasopharyngeal carcinoma.

An individualized immune prognostic signature in nasopharyngeal carcinoma.

Journal: Oral oncology
Published: May 12, 2024

Induction Chemotherapy Followed by Radiotherapy vs Chemoradiotherapy in Nasopharyngeal Carcinoma: A Randomized Clinical Trial.

Induction Chemotherapy Followed by Radiotherapy vs Chemoradiotherapy in Nasopharyngeal Carcinoma: A Randomized Clinical Trial.

Journal: JAMA oncology
Published: February 08, 2024

Apatinib combined with camrelizumab in the treatment of recurrent/metastatic nasopharyngeal carcinoma: a prospective multicenter phase II study.

Apatinib combined with camrelizumab in the treatment of recurrent/metastatic nasopharyngeal carcinoma: a prospective multicenter phase II study.

Journal: Frontiers in immunology
Published: September 21, 2023

Intensity-modulated radiotherapy alone compared with intensity-modulated radiotherapy plus concurrent chemotherapy in intermediate-risk nasopharyngeal carcinoma : A prospective multicenter phase II trial.

Intensity-modulated radiotherapy alone compared with intensity-modulated radiotherapy plus concurrent chemotherapy in intermediate-risk nasopharyngeal carcinoma : A prospective multicenter phase II trial.

Journal: Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
Published: June 14, 2023

Hypofractionated radiotherapy compared with conventionally fractionated radiotherapy to treat initial distant metastases in nasopharyngeal carcinoma: A multicenter, prospective, randomized, phase II trial.

Hypofractionated radiotherapy compared with conventionally fractionated radiotherapy to treat initial distant metastases in nasopharyngeal carcinoma: A multicenter, prospective, randomized, phase II trial.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Published: November 11, 2022

Feasibility and efficiency of double-agent versus single-agent concurrent chemoradiotherapy in patients with nasopharyngeal carcinoma.

Feasibility and efficiency of double-agent versus single-agent concurrent chemoradiotherapy in patients with nasopharyngeal carcinoma.

Journal: Oral oncology
Published: November 17, 2019
Showing 1-8 of 8

Last Updated: 09/26/2026